{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:41:47Z","timestamp":1792662107453,"version":"4.5.0"},"reference-count":32,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/xmxx1378","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T02:53:22Z","timestamp":1767754402000},"page":"9401-9411","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients"],"prefix":"10.62347","volume":"17","author":[{"given":"Lu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41420-025-02498-6","article-title":"Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma","volume":"11","author":"Jia","year":"2025","unstructured":"Jia M, Fu Z, Ye C, Xu W, Liu J, Wu C and Yan H. Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma. Cell Death Discov 2025; 11: 201.","journal-title":"Cell Death Discov"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-025-01252-6","article-title":"Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy","volume":"15","author":"Bal","year":"2025","unstructured":"Bal S, Magnusson T, Ravi G, Giri S, Godby K, Dhakal B, Callander NS, Silbermann RW, Dholaria B, Reddy VB and Costa LJ. Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy. Blood Cancer J 2025; 15: 73.","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Caro J, Cairns D, Menzies T, Boyle E, Pawlyn C, Cook G, Kaiser M, Walker BA, Owen R, Jackson GH, Morgan GJ, Heaney J, Drayson MT and Davies FE. Impact of etiological cytogenetic abnormalities on the depth of immunoparesis and survival in newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 2022; 22: e279-e284.","DOI":"10.1016\/j.clml.2021.10.008"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/biom12010051","article-title":"Progress on the application of bortezomib and bortezomib-based nanoformulations","volume":"12","author":"Liu","year":"2021","unstructured":"Liu J, Zhao R, Jiang X, Li Z and Zhang B. Progress on the application of bortezomib and bortezomib-based nanoformulations. Biomolecules 2021; 12: 51.","journal-title":"Biomolecules"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"9946","DOI":"10.1038\/s41598-025-85398-0","article-title":"VPd as induction therapy in high risk newly diagnosed multiple myeloma","volume":"15","author":"CY","year":"2025","unstructured":"Li CY, Zhong L, Chen DG, Yao FS and Yan H. VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma. Sci Rep 2025; 15: 9946.","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"SZ","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R and Zweegman S. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med 2025; 31: 1195-1202.","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1186\/s12885-025-14087-y","article-title":"Lenalidomide based triplets in relapsed\/refractory multiple myeloma: analysis of the czech myeloma group","volume":"25","author":"Minarik","year":"2025","unstructured":"Minarik J, Pour L, Latal V, Jelinek T, Straub J, Jungova A, Radocha J, Pavlicek P, Stork M, Pika T, Krhovska P, Popkova T, Sedlak F, Spicka I, Jindra P, Capounova V, Maisnar V and Hajek R. Lenalidomide based triplets in relapsed\/refractory multiple myeloma: analysis of the czech myeloma group. BMC Cancer 2025; 25: 651.","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.hoc.2023.12.010","article-title":"Molecular pathogenesis of multiple myeloma: clinical implications","volume":"38","author":"Maura","year":"2024","unstructured":"Maura F and Bergsagel PL. Molecular pathogenesis of multiple myeloma: clinical implications. Hematol Oncol Clin North Am 2024; 38: 267-279.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/10428194.2021.1992615","article-title":"Smoldering multiple myeloma: biology, clinical manifestations and management","volume":"63","author":"Nsiala","year":"2022","unstructured":"Nsiala L, Bobin A, Levy A, Gruchet C, Sabirou F, Gardeney H, Cailly L, Manier S, Moya N, Tomowiak C, Guidez S, Leleu X and Decaux O. Smoldering multiple myeloma: biology, clinical manifestations and management. Leuk Lymphoma 2022; 63: 518-529.","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3390\/ph17070832","article-title":"Targeted delivery strategies for multiple myeloma and their adverse drug reactions","volume":"17","author":"Li","year":"2024","unstructured":"Li S, Wang H, Xiong S, Liu J and Sun S. Targeted delivery strategies for multiple myeloma and their adverse drug reactions. Pharmaceuticals (Basel) 2024; 17: 832.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s13346-022-01268-6","article-title":"A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma","volume":"13","author":"Metselaar","year":"2023","unstructured":"Metselaar J, Lammers T, Boquoi A, Fenk R, Testaquadra F, Schemionek M, Kiessling F, Isfort S, Wilop S and Crysandt M. A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma. Drug Deliv Transl Res 2023; 13: 915-923.","journal-title":"Drug Deliv Transl Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z and Orlowski RZ; IMROZ Study Group. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024; 391: 1597-1609.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"12955","DOI":"10.1038\/s41598-025-97653-5","article-title":"Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation","volume":"15","author":"Huang","year":"2025","unstructured":"Huang Q, Yin X, Guan H, Huang X, Huang B, Xie D and Zhou P. Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation. Sci Rep 2025; 15: 12955.","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-025-01272-2","article-title":"Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1\/CD138\/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide","volume":"15","author":"Cirstea","year":"2025","unstructured":"Cirstea D, Shome R, Samur M, Talluri S, Connolly JJ, Wright AJ, Duvallet E, Joyce ANR, Lively K, Basinsky G, Yee AJ, Chase CC, Malek E, Niesvizky R, Richardson PG and Raje NS. Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1\/CD138\/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide. Blood Cancer J 2025; 15: 77.","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ying L, Zhang X, Lu N, Zhao L, Nie Y, Wang G, Chen S and Xu L. Evaluating the screening value of serum light chain ratio, β2 microglobulin, lactic dehydrogenase and immunoglobulin in patients with multiple myeloma using ROC curves. PLoS One 2023; 18: e0281743.","DOI":"10.1371\/journal.pone.0281743"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","unstructured":"Russell BM and Avigan DE. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. Int J Hematol 2023; 117: 652-659.","journal-title":"Int J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3324\/haematol.2023.284325","article-title":"Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis","volume":"109","author":"PG","year":"2024","unstructured":"Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC and Anderson KC. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica 2024; 109: 2239-2249.","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","article-title":"Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study","volume":"24","author":"Gordan","year":"2024","unstructured":"Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, Fu AZ, Lafeuille MH, Thompson-Leduc P, Khare V, Reitan J, Milkovich G, Kaila S, Davies F and Usmani SZ. Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study. Clin Lymphoma Myeloma Leuk 2024; 24: 55-63.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D’Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M and Boccadoro M. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 2021; 22: 1705-1720.","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","article-title":"The multiple roles of LDH in cancer","volume":"19","author":"Claps","year":"2022","unstructured":"Claps G, Faouzi S, Quidville V, Chehade F, Shen S, Vagner S and Robert C. The multiple roles of LDH in cancer. Nat Rev Clin Oncol 2022; 19: 749-762.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/jcm11102720","article-title":"Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release","volume":"11","author":"Gidaro","year":"2022","unstructured":"Gidaro A, Manetti R, Delitala AP, Soloski MJ, Lambertenghi Deliliers G, Castro D, Soldini D and Castelli R. Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release. J Clin Med 2022; 11: 2720.","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"632399","DOI":"10.3389\/fimmu.2021.632399","article-title":"Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs","volume":"12","author":"D&#x2019","year":"2021","unstructured":"D’Souza C, Prince HM and Neeson PJ. Understanding the role of T-cells in the antimyeloma effect of immunomodulatory drugs. Front Immunol 2021; 12: 632399.","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00520-024-08619-8","article-title":"Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study","volume":"32","author":"Ononogbu","year":"2024","unstructured":"Ononogbu O, Akindele O, Yazdanfard S, Fatima B, Abughosh S and Trivedi MV. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Support Care Cancer 2024; 32: 407.","journal-title":"Support Care Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.26147","article-title":"1 single arm phase II trial","volume":"96","author":"Venner","year":"2021","unstructured":"Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, Chen C, Dolan S, Lalancette M, Louzada M, Kew A, McCurdy A, Monteith B, Reiman T, McDonald G, Sherry M, Gul E, Chen BE and Hay AE. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed\/refractory multiple myeloma: final results from the MCRN-003\/MYX.1 single arm phase II trial. Am J Hematol 2021; 96: 552-560.","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"28557","DOI":"10.1038\/s41598-024-79537-2","article-title":"Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease","volume":"14","author":"Yin","year":"2024","unstructured":"Yin J, Zhou X, Li X, Yuan C, Chu X, Hao L, Wu H and Zhong Y. Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease. Sci Rep 2024; 14: 28557.","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/blctt.s272703","article-title":"Differential diagnosis and therapeutic advances in multiple myeloma: a review article","volume":"13","author":"Hussain","year":"2023","unstructured":"Hussain M, Yellapragada S and Al Hadidi S. Differential diagnosis and therapeutic advances in multiple myeloma: a review article. Blood Lymphat Cancer 2023; 13: 33-57.","journal-title":"Blood Lymphat Cancer"},{"key":"ref26","unstructured":"Nižňanská D, Vlachová M, Gregorová J, Kotašková J, Jarošová M and Ševčíková S. Molecular basis of multiple myeloma. Klin Onkol 2024; 37: 27-33."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.3390\/cancers14163884","article-title":"Calorimetric markers for detection and monitoring of multiple myeloma","volume":"14","author":"Krumova","year":"2022","unstructured":"Krumova S, Todinova S and Taneva SG. Calorimetric markers for detection and monitoring of multiple myeloma. Cancers (Basel) 2022; 14: 3884.","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/17474086.2024.2326219","article-title":"Pomalidomide combined with dexamethasone for the treatment of relapsed\/refractory multiple myeloma: a systematic review and meta-analysis","volume":"17","author":"Luo","year":"2024","unstructured":"Luo Y, Li C, Niu Y, Wu S, Tian J, Hu Z, He J, Zhang Z, Liu H, Li Y, Wang T and Fang Y. Pomalidomide combined with dexamethasone for the treatment of relapsed\/refractory multiple myeloma: a systematic review and meta-analysis. Expert Rev Hematol 2024; 17: 127-134.","journal-title":"Expert Rev Hematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/ph16010111","article-title":"Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies","volume":"16","author":"Kozalak","year":"2023","unstructured":"Kozalak G, Bütün İ, Toyran E and Koşar A. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel) 2023; 16: 111.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/jpm13040695","article-title":"Bortezomib pharmacogenetic biomarkers for the treatment of multiple myeloma: review and future perspectives","volume":"13","author":"Sanz-Solas A","year":"2023","unstructured":"Sanz-Solas A, Labrador J, Alcaraz R, Cuevas B, Vinuesa R, Cuevas MV and Saiz-Rodríguez M. Bortezomib pharmacogenetic biomarkers for the treatment of multiple myeloma: review and future perspectives. J Pers Med 2023; 13: 695.","journal-title":"J Pers Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12888-024-06024-3","article-title":"A predictive model for readmission within 1-year post-discharge in patients with schizophrenia","volume":"24","author":"Hou","year":"2024","unstructured":"Hou M, Wu Y, Xue J, Chen Q, Zhang Y, Zhang R, Yu L, Wang J, Zhou Z and Li X. A predictive model for readmission within 1-year post-discharge in patients with schizophrenia. BMC Psychiatry 2024; 24: 573.","journal-title":"BMC Psychiatry"}],"container-title":["American Journal of Translational Research"],"original-title":[],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:16:23Z","timestamp":1792660583000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/12\/ajtr0168085.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/xmxx1378","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}